These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 12637215)

  • 41. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87.
    Einsiedel HG; von Stackelberg A; Hartmann R; Fengler R; Schrappe M; Janka-Schaub G; Mann G; Hählen K; Göbel U; Klingebiel T; Ludwig WD; Henze G
    J Clin Oncol; 2005 Nov; 23(31):7942-50. PubMed ID: 16258094
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas.
    Hiraga S; Arita N; Ohnishi T; Kohmura E; Yamamoto K; Oku Y; Taki T; Sato M; Aozasa K; Yoshimine T
    J Neurosurg; 1999 Aug; 91(2):221-30. PubMed ID: 10433310
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Is high dose methotrexate without irradiation of the brain sufficiently effective in prevention of CNS disease in children with acute lymphoblastic leukemia?
    Cáp J; Foltinová A; Kaiserová E; Mojzesová A; Sejnová D; Jamárik M
    Neoplasma; 1998; 45(3):176-9. PubMed ID: 9717531
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intermediate-dose methotrexate versus cranial irradiation in childhood acute lymphoblastic leukemia: a ten-year follow-up.
    Freeman AI; Boyett JM; Glicksman AS; Brecher ML; Leventhal BG; Sinks LF; Holland JF
    Med Pediatr Oncol; 1997 Feb; 28(2):98-107. PubMed ID: 8986145
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oxidative changes in cerebral spinal fluid phosphatidylcholine during treatment for acute lymphoblastic leukemia.
    Miketova P; Kaemingk K; Hockenberry M; Pasvogel A; Hutter J; Krull K; Moore IM
    Biol Res Nurs; 2005 Jan; 6(3):187-95. PubMed ID: 15583359
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risk factors and therapy for isolated central nervous system relapse of pediatric acute myeloid leukemia.
    Johnston DL; Alonzo TA; Gerbing RB; Lange BJ; Woods WG
    J Clin Oncol; 2005 Dec; 23(36):9172-8. PubMed ID: 16361619
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group.
    Matloub Y; Lindemulder S; Gaynon PS; Sather H; La M; Broxson E; Yanofsky R; Hutchinson R; Heerema NA; Nachman J; Blake M; Wells LM; Sorrell AD; Masterson M; Kelleher JF; Stork LC;
    Blood; 2006 Aug; 108(4):1165-73. PubMed ID: 16609069
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture.
    Bürger B; Zimmermann M; Mann G; Kühl J; Löning L; Riehm H; Reiter A; Schrappe M
    J Clin Oncol; 2003 Jan; 21(2):184-8. PubMed ID: 12525508
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study.
    Mahoney DH; Shuster JJ; Nitschke R; Lauer S; Steuber CP; Camitta B
    J Clin Oncol; 2000 Mar; 18(6):1285-94. PubMed ID: 10715299
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High-dose methotrexate in acute lymphocytic leukemia.
    Freeman AI; Wang JJ; Sinks LF
    Cancer Treat Rep; 1977 Jul; 61(4):727-31. PubMed ID: 267510
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate.
    Pfeifer H; Wassmann B; Hofmann WK; Komor M; Scheuring U; Brück P; Binckebanck A; Schleyer E; Gökbuget N; Wolff T; Lübbert M; Leimer L; Gschaidmeier H; Hoelzer D; Ottmann OG
    Clin Cancer Res; 2003 Oct; 9(13):4674-81. PubMed ID: 14581336
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia.
    Skärby TV; Anderson H; Heldrup J; Kanerva JA; Seidel H; Schmiegelow K;
    Leukemia; 2006 Nov; 20(11):1955-62. PubMed ID: 16990760
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma.
    Burkhardt B; Woessmann W; Zimmermann M; Kontny U; Vormoor J; Doerffel W; Mann G; Henze G; Niggli F; Ludwig WD; Janssen D; Riehm H; Schrappe M; Reiter A
    J Clin Oncol; 2006 Jan; 24(3):491-9. PubMed ID: 16421426
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Accretion of bone mass in patients treated for childhood acute lymphoblastic leukemia].
    Muszyńska-Rosłan K; Konstantynowicz J; Krawczuk-Rybak M
    Pol Merkur Lekarski; 2007 Oct; 23(136):271-5. PubMed ID: 18293849
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CNS late-effects after ALL therapy in childhood. Part III: neuropsychological performance in long-term survivors of childhood ALL: impairments of concentration, attention, and memory.
    Langer T; Martus P; Ottensmeier H; Hertzberg H; Beck JD; Meier W
    Med Pediatr Oncol; 2002 May; 38(5):320-8. PubMed ID: 11979456
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience.
    Goldberg JM; Silverman LB; Levy DE; Dalton VK; Gelber RD; Lehmann L; Cohen HJ; Sallan SE; Asselin BL
    J Clin Oncol; 2003 Oct; 21(19):3616-22. PubMed ID: 14512392
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials.
    Clarke M; Gaynon P; Hann I; Harrison G; Masera G; Peto R; Richards S;
    J Clin Oncol; 2003 May; 21(9):1798-809. PubMed ID: 12721257
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia.
    Cortes J; O'Brien SM; Pierce S; Keating MJ; Freireich EJ; Kantarjian HM
    Blood; 1995 Sep; 86(6):2091-7. PubMed ID: 7662956
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Effects of prophylactic treatment of central nervous system leukemia in children. Analysis of CNS prophylactic treatment with cyclic high dose multichemotherapy, craniospinal irradiation, and high dose infusion of MTX].
    Abe Y; Asakura A; Endo N
    Gan To Kagaku Ryoho; 1982 May; 9(5):855-65. PubMed ID: 6964040
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Utility of cranial boost in addition to total body irradiation in the treatment of high risk acute lymphoblastic leukemia.
    Alexander BM; Wechsler D; Braun TM; Levine J; Herman J; Yanik G; Hutchinson R; Pierce LJ
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1191-6. PubMed ID: 15978741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.